<?xml version="1.0" encoding="UTF-8" ?>
			<?xml-stylesheet href="/rss/rss2html.xsl" type="text/xsl" media="screen"?>
			<rss version="2.0" xmlns:alacra="http://www.alacra.com" xmlns:ccbn="http://www.alacra.com/ccbn" xmlns:srp="http://www.alacra.com/srp" xmlns:newstex="http://www.alacra.com/newstex" ><channel><title>Altus Pharmaceuticals Inc. RSS Research Feed - Subscribe Today - AlacraStore.com</title>
<description>Altus Pharmaceuticals Inc.</description>
<link>http://www.alacrastore.com/company-snapshot/Altus_Pharmaceuticals_Inc-2520225</link>
<lastBuildDate>08 Nov 2009 07:27:34 EST</lastBuildDate>
<alacra:xlsid>2520225</alacra:xlsid>
<alacra:company>Altus Pharmaceuticals Inc.</alacra:company>
<language>en</language>
<generator>AlacraStore RSS Builder 1.0</generator>
<ttl>30</ttl>
<item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-37128315</link><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-37128315</newstex:docid><guid isPermaLink="false">newstex/BW-0001-37128315</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><newstex:Contributor xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Contributor><newstex:CopyrightDate xmlns:newstex="http://www.alacra.com/newstex">2005</newstex:CopyrightDate><newstex:CreditLine xmlns:newstex="http://www.alacra.com/newstex">Altus Pharmaceuticals Inc.</newstex:CreditLine><newstex:Provider xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Provider><newstex:ProviderId xmlns:newstex="http://www.alacra.com/newstex">newstex.com</newstex:ProviderId><newstex:PublicIdentifier xmlns:newstex="http://www.alacra.com/newstex">newstexBW-0001-37128315</newstex:PublicIdentifier><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><newstex:PublicationCode xmlns:newstex="http://www.alacra.com/newstex">0001</newstex:PublicationCode><newstex:Publisher xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publisher><newstex:PublisherCode xmlns:newstex="http://www.alacra.com/newstex">BW</newstex:PublisherCode><newstex:RevisionId xmlns:newstex="http://www.alacra.com/newstex">1</newstex:RevisionId><newstex:Source xmlns:newstex="http://www.alacra.com/newstex">Newstex Inc.</newstex:Source><newstex:SourceId xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:SourceId><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016019</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>11 Aug 2009 10:32:29 EST</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18012000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18013000</newstex:event><newstex:loaddate xmlns:newstex="http://www.alacra.com/newstex">8/11/2009</newstex:loaddate><title>Altus Pharmaceuticals Inc. Receives NASDAQ Notice of Noncompliance</title><description> Aug. ##, #### (Business Wire) --  Altus Pharmaceuticals Inc. (Nasdaq: ALTU) today announced that on August #, #### it was advised by The NASDAQ Stock Market (NASDAQ) that, based on the CompanyÂ’s stockholders equity as reported in the...</description><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ALTUS PHARMACEUTICALS INC.</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">NASDAQ STOCK MARKET INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">ALTU</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">NDAQ</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T2216248</link><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T2216248</ccbn:docid><guid isPermaLink="false">ccbn/T2216248</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><pubDate>11 May 2009 12:07:00 EST</pubDate><ccbn:eventid xmlns:ccbn="http://www.alacra.com/ccbn">2216248</ccbn:eventid><ccbn:headline xmlns:ccbn="http://www.alacra.com/ccbn">Final Transcript of ALTU earnings conference call or presentation, 11-May-09 11:00am ET</ccbn:headline><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Altus Pharmaceuticals Inc.</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Altus Pharmaceuticals Inc. Q1 2009 Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">ALTU</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Altus Pharmaceuticals Inc. Q1 2009 Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><description>...Thomas J. Phair, Jr. Altus Pharmaceuticals Inc. - Principal Accounting &amp; Financial Officer, VP-Finance, Treasurer &amp; Corp. Controller Georges Gemayel, Ph.D. Altus Pharmaceuticals Inc. - President &amp; CEO P R E S E N T A T I O N...

</description><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T2125753</link><guid isPermaLink="false">ccbn/T2125753</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T2125753</ccbn:docid><description>...Good day and welcome to this conference call with Altus Pharmaceuticals regarding the Company's fourth-quarter financial results. This call is being recorded. I will now turn the call over to Altus Senior Director of Corporate Communications, Mr. John Jordan. Please go ahead, sir. ...

</description><pubDate>11 Mar 2009 12:06:00 EST</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Altus Pharmaceuticals Inc.</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Altus Pharmaceuticals Inc. Q4 2008 Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">ALTU</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Altus Pharmaceuticals Inc. Q4 2008 Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T2081461</link><guid isPermaLink="false">ccbn/T2081461</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T2081461</ccbn:docid><description>...Good day and welcome to today's Altus Pharmaceuticals investor conference call. Today's call is being recorded. At this time, for opening remarks and introductions, I'd like to turn the call over to Ms. Kari Watson. Please go ahead. ...

</description><pubDate>26 Jan 2009 04:04:00 EST</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Altus Pharmaceuticals Inc.</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Altus Pharmaceuticals Inc. Realigns Product Development Priorities and Focuses on Long-Acting Growth Hormone Candidate ALTU-238 Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">ALTU</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">9:00am ET</ccbn:time><title>Altus Pharmaceuticals Inc. Realigns Product Development Priorities and Focuses on Long-Acting Growth Hormone Candidate ALTU-238 Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/srp/834938756</link><srp:docid xmlns:srp="http://www.alacra.com/srp">834938756</srp:docid><guid isPermaLink="false">srp/834938756</guid><srp:index_mode xmlns:srp="http://www.alacra.com/srp">norm</srp:index_mode><srp:cik xmlns:srp="http://www.alacra.com/srp">0001340744</srp:cik><srp:company xmlns:srp="http://www.alacra.com/srp">834938756</srp:company><srp:cusip xmlns:srp="http://www.alacra.com/srp">02216N105</srp:cusip><pubDate>06 Oct 2006 12:37:00 EST</pubDate><srp:file xmlns:srp="http://www.alacra.com/srp">Altus_Pharmaceuticals_Inc_ALTU_Defense_Analytics_Profile.pdf</srp:file><title>Altus Pharmaceuticals Inc.</title><srp:ticker xmlns:srp="http://www.alacra.com/srp">ALTU</srp:ticker><description>...(#) Percentages are based upon the number of eligible and active companies in the SharkRepellent.net database. For the Poison Pill In Force calculation by index, non-US companies are included. (#) Supermajority vote requirement (e.g., ##.##%, ##%, ##%) for shareholders to amend/repeal at least one charter or bylaw provision. (#) SIC Group is defined as the first two digits of this company's primary SIC code (##: Chemicals And Allied Products). There are ### eligible and active companies in the SharkRepellent.net database in this SIC group. (#) The FactSet Bullet Proof Rating is a weighted average index comprised of significant components that impact takeover defenses. The rating scale is from # to ## with a ## representing the most formidable defenses. The rating system is a relative measurement and is not intended to measure the probability of a successful defense....

</description><category>Credit &amp; Investment Research</category><alacra:ip>SharkRepellent.net</alacra:ip></item></channel></rss>